Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study
- PMID: 20145609
- PMCID: PMC2898908
- DOI: 10.1038/ajg.2010.18
Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study
Abstract
Objectives: The significance of nonalcoholic fatty liver disease (NAFLD) among patients with diabetes is unknown. We sought to determine whether a diagnosis of NAFLD influenced mortality among a community-based cohort of patients with type II diabetes mellitus.
Methods: A total of 337 residents of Olmsted County, Minnesota with diabetes mellitus diagnosed between 1980 and 2000 were identified using the Rochester Epidemiology Project and the Mayo Laboratory Information System, and followed for 10.9 + or - 5.2 years (range 0.1-25). Survival was analyzed using Cox proportional hazards modeling, with NAFLD treated as a time-dependent covariate.
Results: Among the 337 residents, 116 were diagnosed with NAFLD 0.9 + or - 4.6 years after diabetes diagnosis. Patients with NAFLD were younger, and more likely to be female and obese. Overall, 99/337 (29%) patients died. In multivariate analysis to adjust for confounders, overall mortality was significantly associated with a diagnosis of NAFLD (hazard ratio (HR) 2.2; 95% confidence interval (CI) 1.1, 4.2; P=0.03), presence of ischemic heart disease (HR 2.3; 95% CI 1.2, 4.4), and duration of diabetes (HR per 1 year, 1.1; 95% CI 1.03, 1.2). The most common causes of death in the NAFLD cohort were malignancy (33% of deaths), liver-related complications (19% of deaths), and ischemic heart disease (19% of deaths). In adjusted multivariate models, NAFLD was borderline associated with an increased risk of dying from malignancy (HR 2.3; 95% CI 0.9, 5.9; P=0.09) and not from cardiovascular disease (HR 0.9; 95% CI 0.3, 2.4; P=0.81).
Conclusions: The diagnosis of NAFLD is associated with an increased risk of overall death among patients with diabetes mellitus.
Conflict of interest statement
Which author is the guarantor of the manuscript? Leon Adams
What was each author's contribution to the paper? Leon Adams contributed to study design, data collection and analysis and interpretation and manuscript writing.
Scott Harmsen, Jennifer L. St.Sauver and Felicity B. Enders all contributed to the study design, data analysis and interpretation.
Terry Therneau contributed to the data analysis and interpretation.
Phunchai Charatcharoenwitthaya contributed to the data collection and manuscript preparation.
Paul Angulo contributed to study design, data analysis and interpretation and manuscript writing.
What financial support was given to the project? The study was supported by an R01 DK82426 to Dr Paul Angulo. Dr Leon Adams was sponsored by medical research scholarships from the National Health and Medical Research Council (No. 353710) and The University of Western Australia (Athelstan and Amy Saw Scholarship).
What potential competing interests exist? None.
Similar articles
-
The natural history of nonalcoholic fatty liver disease: a population-based cohort study.Gastroenterology. 2005 Jul;129(1):113-21. doi: 10.1053/j.gastro.2005.04.014. Gastroenterology. 2005. PMID: 16012941
-
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.World J Gastroenterol. 2013 Feb 28;19(8):1219-29. doi: 10.3748/wjg.v19.i8.1219. World J Gastroenterol. 2013. PMID: 23482703 Free PMC article.
-
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.Am J Gastroenterol. 2008 Sep;103(9):2263-71. doi: 10.1111/j.1572-0241.2008.02034.x. Epub 2008 Aug 5. Am J Gastroenterol. 2008. PMID: 18684196 Free PMC article.
-
Extrahepatic complications of nonalcoholic fatty liver disease.Hepatology. 2014 Mar;59(3):1174-97. doi: 10.1002/hep.26717. Epub 2014 Jan 16. Hepatology. 2014. PMID: 24002776 Review.
-
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.J Gastroenterol Hepatol. 2016 May;31(5):936-44. doi: 10.1111/jgh.13264. J Gastroenterol Hepatol. 2016. PMID: 26667191 Review.
Cited by
-
Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements.Biomedicines. 2024 Jan 30;12(2):323. doi: 10.3390/biomedicines12020323. Biomedicines. 2024. PMID: 38397925 Free PMC article.
-
The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review.Afr Health Sci. 2023 Jun;23(2):509-518. doi: 10.4314/ahs.v23i2.59. Afr Health Sci. 2023. PMID: 38223606 Free PMC article.
-
Fibroblast Growth Factor 21: A More Effective Biomarker Than Free Fatty Acids and Other Insulin Sensitivity Measures for Predicting Non-alcoholic Fatty Liver Disease in Saudi Arabian Type 2 Diabetes Patients.Cureus. 2023 Dec 14;15(12):e50524. doi: 10.7759/cureus.50524. eCollection 2023 Dec. Cureus. 2023. PMID: 38222178 Free PMC article.
-
The Independent Association of Non-alcoholic Fatty Liver Disease With Incident Cardiovascular Disease: A GRADE Evaluation of the Evidence Through a Systematic Review and Meta-analysis.J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101277. doi: 10.1016/j.jceh.2023.08.013. Epub 2023 Sep 9. J Clin Exp Hepatol. 2024. PMID: 38076375
-
Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease-A Single Blinded Crossover Trial.Nutrients. 2023 Nov 22;15(23):4870. doi: 10.3390/nu15234870. Nutrients. 2023. PMID: 38068729 Free PMC article. Clinical Trial.
References
-
- Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. - PubMed
-
- Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–1393. - PubMed
-
- Browning J, Szczepaniak L, Dobbins R, et al. Prevalence of Hepatic Steatosis in an Urban Population in the United States: Impact of Ethnicity. Hepatology. 2004;40:1387–1395. - PubMed
-
- Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79. - PubMed
-
- Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. Jama. 2003;290:1884–1890. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
